Stock STAGR STALLERGENES GREER
Add to a list
To use this feature you must be a member
Log inSign up

Financials Stallergenes Greer

Equities

STAGR

GB00BZ21RF93

Pharmaceuticals

Real-time Euronext Paris
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Stallergenes Greer +0.14% +29.68%
2023 Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes CI
2023 Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 608.6 759.5 558.6 724 724 724
Enterprise Value (EV) 1 560.5 727.2 503.4 764.2 961.3 973.1
P/E ratio -10.1 x -77 x 43.8 x 21.7 x 21.5 x 11.9 x
Yield - - - - - -
Capitalization / Revenue 3.27 x 2.92 x 2.02 x 2.39 x 2.38 x 2.21 x
EV / Revenue 3.01 x 2.79 x 1.82 x 2.53 x 3.16 x 2.97 x
EV / EBITDA -7.78 x 54.1 x 13.6 x 11.5 x 11.5 x 9.46 x
EV / FCF -8.52 x -50.4 x 27.1 x 28.6 x 20.3 x 18.5 x
FCF Yield -11.7% -1.98% 3.69% 3.5% 4.93% 5.42%
Price to Book 1.25 x 1.7 x 1.19 x 1.93 x 5.55 x 6.04 x
Nbr of stocks (in thousands) 19,697 19,722 19,737 19,728 19,728 19,728
Reference price 2 30.90 38.51 28.30 36.70 36.70 36.70
Announcement Date 4/28/17 4/16/18 3/21/19 10/26/20 10/14/21 5/6/22
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 186.4 260.2 277.1 302.5 303.9 328.1
EBITDA 1 -72.04 13.45 36.89 66.18 83.75 102.8
EBIT 1 -92.54 -5.21 20.88 50.23 67.6 88.77
Operating Margin -49.65% -2% 7.54% 16.6% 22.24% 27.06%
Earnings before Tax (EBT) 1 -96.3 -7.726 16.67 45.01 56.89 85.75
Net income 1 -60.52 -9.871 12.76 33.3 33.7 60.67
Net margin -32.47% -3.79% 4.61% 11.01% 11.09% 18.49%
EPS 2 -3.070 -0.5001 0.6465 1.688 1.708 3.084
Free Cash Flow 1 -65.77 -14.42 18.59 26.72 47.35 52.74
FCF margin -35.29% -5.54% 6.71% 8.83% 15.58% 16.08%
FCF Conversion (EBITDA) - - 50.4% 40.38% 56.54% 51.3%
FCF Conversion (Net income) - - 145.73% 80.25% 140.49% 86.93%
Dividend per Share - - - - - -
Announcement Date 4/28/17 4/16/18 3/21/19 10/26/20 10/14/21 5/6/22
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - - - 40.2 237 249
Net Cash position 1 48.2 32.3 55.2 - - -
Leverage (Debt/EBITDA) - - - 0.6076 x 2.833 x 2.422 x
Free Cash Flow 1 -65.8 -14.4 18.6 26.7 47.4 52.7
ROE (net income / shareholders' equity) -11.8% -2.11% 2.78% 7.86% 13.3% 48.6%
ROA (Net income/ Total Assets) -8.79% -0.56% 2.34% 5.47% 7.7% 10.4%
Assets 1 688.6 1,774 544.8 609 438 583
Book Value Per Share 2 24.80 22.70 23.90 19.00 6.610 6.070
Cash Flow per Share 2 3.610 2.580 3.750 3.210 3.210 4.300
Capex 1 22 12.6 24.9 16 12.7 16.8
Capex / Sales 11.81% 4.86% 8.97% 5.29% 4.19% 5.11%
Announcement Date 4/28/17 4/16/18 3/21/19 10/26/20 10/14/21 5/6/22
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
STALLERGENES GREER Stock Stallergenes Greer
+29.68% 0
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. STAGR Stock
  4. Financials Stallergenes Greer